EA202092017A1 - NEW GLP-1 ANALOGUES - Google Patents

NEW GLP-1 ANALOGUES

Info

Publication number
EA202092017A1
EA202092017A1 EA202092017A EA202092017A EA202092017A1 EA 202092017 A1 EA202092017 A1 EA 202092017A1 EA 202092017 A EA202092017 A EA 202092017A EA 202092017 A EA202092017 A EA 202092017A EA 202092017 A1 EA202092017 A1 EA 202092017A1
Authority
EA
Eurasian Patent Office
Prior art keywords
analogs
present
glp
action
analogues
Prior art date
Application number
EA202092017A
Other languages
Russian (ru)
Inventor
Раджаманнар Тхеннати
Нишитх Чатурведи
Винод Сампатрао Бураде
Прадип Динеш Шахи
Мутхукумаран Натараджан
Равишанкара Мадавати Нагараджа
Ришит Мансухлал Залавадия
Кунал Пандья
Бриджешкумар Пейтел
Дхирен Рамешчандра Джоши
Крунал Харишбхай Сони
Абхишек Тивари
Випулкумар Шанкарбхай Пейтел
Original Assignee
Сан Фармасьютикал Индастриз Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сан Фармасьютикал Индастриз Лимитед filed Critical Сан Фармасьютикал Индастриз Лимитед
Priority claimed from PCT/IB2019/052835 external-priority patent/WO2019193576A1/en
Publication of EA202092017A1 publication Critical patent/EA202092017A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к новым аналогам глюкагоноподобного пептида-1 (GLP-1) (7-37), имеющим аминокислотную последовательность с Leu или Ile на C-конце. Новые аналоги являются высокоактивными агонистами GLP-1 со сниженным количеством нежелательных эффектов и увеличенной продолжительностью действия. Настоящее изобретение также относится к ацилированным производным новых аналогов, которые характеризуются дополнительно увеличенной активностью и продолжительностью действия и подходят для перорального введения. Аналоги по настоящему изобретению могут найти применение в лечении диабета и ожирения.The present invention relates to novel analogs of glucagon-like peptide-1 (GLP-1) (7-37) having the amino acid sequence with Leu or Ile at the C-terminus. The new analogs are highly active GLP-1 agonists with reduced unwanted effects and increased duration of action. The present invention also relates to acylated derivatives of the novel analogs which are further enhanced in activity and duration of action and are suitable for oral administration. The analogs of the present invention may find use in the treatment of diabetes and obesity.

EA202092017A 2018-10-26 2019-04-05 NEW GLP-1 ANALOGUES EA202092017A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201821040474 2018-10-26
PCT/IB2019/052835 WO2019193576A1 (en) 2018-04-05 2019-04-05 Novel glp-1 analogues

Publications (1)

Publication Number Publication Date
EA202092017A1 true EA202092017A1 (en) 2021-02-10

Family

ID=74855471

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092017A EA202092017A1 (en) 2018-10-26 2019-04-05 NEW GLP-1 ANALOGUES

Country Status (1)

Country Link
EA (1) EA202092017A1 (en)

Similar Documents

Publication Publication Date Title
ZA202306729B (en) Novel glp-1 analogues
EA202090392A3 (en) GIP AND GLP-1 COAGONIST COMPOUNDS
MY197569A (en) Gip/glp1 co-agonist compounds
EA202192588A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING PH20 VARIANT OF HUMAN HYALURONIDASE AND DRUG FOR SUBCUTANEOUS ADMINISTRATION
EA201991345A1 (en) NEW COMPOUNDS AS PEPTIDE TRIPLE GLP1 / GLUCAGON / GIP RECEPTOR AGONISTS
EA201690660A1 (en) CONNECTIONS AND METHODS BASED ON DOUBLE AGONIST OF GIP AND GLP-1
PE20200606A1 (en) SOLID COMPOSITIONS FOR ORAL ADMINISTRATION
RU2015101697A (en) GLUCAGON ANALOGUES WITH GIP RECEPTOR ACTIVITY
JP2014504588A5 (en)
PE20090932A1 (en) COMPOUNDS THAT EXHIBIT GLUCAGON ANTAGONIST AND GLP-1 AGONIST ACTIVITY
AR094181A1 (en) GLP1 / GIP OR TRIGONAL DUAL AGONISTS OF GLP1 / GIP / GLUCAGON
EA201270723A1 (en) NEW PEPTIDES AND METHODS FOR THEIR RECEPTION AND APPLICATION
CO6280539A2 (en) MIXED AGONISTS, BASED ON GIP FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY
PE20120563A1 (en) NOVEL CONSTRUCTIONS OF HUMAN PAPILLOMA VIRUS (HPV) PROTEIN AND ITS USE IN THE PREVENTION OF HPV DISEASE
AR067555A1 (en) DERIVATIVE OF INSULINOTROPIC PEPTIDE IN WHICH THE N-TERMINAL AMINO ACID IS MODIFIED
GT201700224A (en) RGMA BINDING PROTEIN AND ITS USE
JP2018504901A5 (en)
MX2020008387A (en) Therapeutic uses of glp1r agonists.
EA202091095A1 (en) ORAL DELIVERY OF GLP-1 PEPTIDE ANALOGUES
MX2022009149A (en) Gip/glp1 co-agonist compounds.
EA200800181A1 (en) PHARMACEUTICAL COMPOSITION GLP-1
MX2020001761A (en) Acylated oxyntomodulin peptide analog.
PH12021551243A1 (en) Oxyntomodulin peptide analog formulations
EA202092017A1 (en) NEW GLP-1 ANALOGUES
PE20221518A1 (en) INCRETIN ANALOGS AND THEIR USES